What is MLTX's market cap?

$970.22M, based on the Nov 4 close of $11.40.

Does MoonLake Immunotherapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of MLTX is sold short?

7.8M shares, 14.3% of float, as of Oct 15, 2026.

What sector is MLTX in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · MLTXHealthcarePharmaceuticals

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)

$11.40−2.56%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$11.47▲ 12.45% in range

Nov 3, 2025Low $9.55 · High $22.16Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

MoonLake Immunotherapeutics closed at $11.40 on Nov 4, down 2.56%, 48.6% below its 52-week closing high. Volume of 701.5K shares was 0.38× its 20-day average (below normal).

Split-adjusted performance: +4.1% over one month, -35.6% over six months, +11.8% over one year.

Short interest was 7.8M shares at the Oct 15 settlement, down 2.7% from the prior report (14.3% of float, 4.1 days to cover).

Market cap$970.2M85.1M shares

Revenue · quarter$0.00—

Diluted EPS$-0.84—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range9.55 – 22.16−48.6% from high

Volume701.5K0.38× 20-day avg

Volatility · 60d57.1%Annualised

Short % of float14.3%4.1 days to cover

Net cash$437.5MCash $537.0M

Next earnings—Not scheduled

Split-adjusted performance

1W −7.4%1M +4.1%3M −36.8%6M −35.6%YTD −13.5%1Y +11.8%3Y −76.7%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum37

Revenue growth—

Net margin—

Value (low P/E)—

Size71

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short7.8M−2.7% vs prior

Days to cover4.1Settled Oct 15

% of float14.3%

Short vol. 10d45.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
MLTXMoonLake Immunotherapeutics	$11.40	−2.56%	−35.6%	—	—	—	$970.2M
RIGLRigel Pharmaceuticals Inc. (New)	$51.44	+5.27%	+92.9%	−22.6%	22.0%	3.0	$960.8M	Compare
ORICOric Pharmaceuticals	$9.20	−4.07%	−1.1%	—	—	—	$953.6M	Compare
LTGOLatigo Biotherapeutics	$14.37	−1.37%	—	—	—	—	$952.7M	Compare
SVRASavara	$4.60	−3.15%	−12.7%	—	—	—	$945.2M	Compare
JBIOJade Biosciences	$14.77	+1.37%	−41.2%	—	—	—	$939.3M	Compare
SNDXSyndax Pharmaceuticals	$10.48	−26.66%	−49.2%	+81.6%	−59.3%	—	$935.8M	Compare
ANROAlto Neuroscience	$22.94	+1.06%	−6.3%	—	—	—	$900.2M	Compare
CRVSCorvus Pharmaceuticals	$10.39	+5.70%	−32.8%	—	—	—	$874.0M	Compare

News about MoonLake Immunotherapeutics

All news →

MoonLake Immunotherapeutics' CFO Sells 39K SharesThe Motley Fool · Jul 3, 2026Neutral MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingGlobeNewswire Inc. · Jun 24, 2026▲ Positive The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?The Motley Fool · Apr 18, 2026Neutral Biotech Fund BVF Trims MoonLake Stake, Sells $63M in SharesThe Motley Fool · Apr 7, 2026Neutral MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual MeetingGlobeNewswire Inc. · Mar 28, 2026▲ Positive

Quick answers

What does MoonLake Immunotherapeutics do?: MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
What is MLTX's market cap?: $970.22M, based on the Nov 4 close of $11.40.
Does MoonLake Immunotherapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of MLTX is sold short?: 7.8M shares, 14.3% of float, as of Oct 15, 2026.
What sector is MLTX in?: Healthcare, in the Pharmaceuticals industry.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

HQ: Zug, V8130 employeesListed Apr 6, 2022moonlaketx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology